0481

EFFECT OF INHALED BUDESONIDE AND FORMOTEROL IN TREATING MODERATE PERSISTENT CHILDREN ASTHMA

Xu LL, Ling XY, Hua XL

Union Hospital, Fujian Medical University, Fuzhou, China

Objective: To evaluate the effects of adding formorterol to Inhaled budesonide (BUD) in treating moderate persistent children asthma.

Methods: Fifty patients with moderate persistent asthma were randomly divided into two groups: inhaled BUD 200μg/d qd plus formoterol tablets 4 μg/kg.d bid in groupsⅠand inhaled BUD 400μg/d qd in groupsⅡ, treatment Continued for 3 months. The efficacy between groupsⅠand groupsⅡ were compared by symptoms scores , PEF% predicted and daily PEF Variability(PEFV %).

Results: Symptoms scores ( 2.6±0.4 vs 1.3±0.7 in groupⅠ, 2.7±0.3 vs 1.4±0.6 in groupsⅡ), and lung function (PEF % 70.2±4.8% vs 99.3±5.4 % in groupⅠ，71.6±4.5% vs 101.8±8.6 % in group Ⅱ and PEFV% 34.1±3.4% vs 21.7±4.3% in groupⅠ，33.6±3.2% vs 22.0±.38% in group Ⅱ) had obvious difference between the patients before treatment and those after treatment three months (P<0.01, respectively), the improvements with formoterol were greater after treatment one month (p<0.05). But the total effective rates in both groups were alike（100% vs100%）after treatment 3 moths.

Conclusion: In symptomatic children with moderate asthma (especially for nighttime symptoms) taking low to moderate doses of inhaled steroids, the therapy of adding the long-acting β₂-agonist may replace that therapy of alone increasing corticosteroids dosage.